DNA Array Analysis of Patients With Cervical Cancer

A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00512551

Enrollment

Registered

2007-08-07

Start date

2000-06-20

Completion date

2017-11-20

Last updated

2017-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

Cervical Cancer, DNA Array Analysis, Gene Expression, DNA

Brief summary

The goal of this clinical research study is to find out if the expression of certain genes is linked with the response of cervical cancer to radiation. Researchers will study a large number of genes located in tumor material to learn this information.

Detailed description

Patients in this study are already scheduled to begin radiation therapy. Researchers will get tumor cells by taking two biopsies of the cervix. The first biopsy of the cervical tumor will be done before any treatment is given. The second biopsy will be performed about 48 hours after the radiation treatment has begun. They will then study the cells in the lab with a new technique for studying gene expression called DNA array, as well as human papillomavirus (HPV) analysis, quantification of apoptosis levels, hematoxylin and eosin staining, and storage of tissue for future research. The patterns of gene expression in the biopsies will be compared with the success of radiation treatments. Some of the material will also be stored and used in the future for other research projects. This is an investigational study. A total of 18 patients will take part in this study. All will be enrolled at UTMDACC.

Interventions

PROCEDURETumor Biopsies

Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

1. Newly diagnosed cervical cancer: clinical Stage IB -IIIB 2. Invasive pure squamous cell carcinoma 3. Planned treatment with concurrent cisplatinum/5-fluorouracil chemotherapy and pelvic radiation

Exclusion criteria

1\. Previous cervical cancer treatment including but not limited to transvaginal cone irradiation

Design outcomes

Primary

Measure	Time frame
The goal of this clinical research study is to find out if the expression of certain genes is linked with the response of cervical cancer to radiation.	8 Years

Secondary

Measure	Time frame
Researchers will study a large number of genes located in tumor material to learn this information.	8 Years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026